Screener
ARS Pharmaceuticals, Inc. SPRY Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026.
- Filed
- May 15, 2026, 6:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-225142
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Product revenue, net | $17,452 | $7,763 |
| Revenue under collaboration agreements | 2,489 | 210 |
| Revenue under supply agreements | 2,740 | — |
| Total revenue | 22,681 | 7,973 |
| Operating expenses: | ||
| Cost of goods sold (including related party amounts of $1,233 and $488, respectively) | 6,286 | 1,094 |
| Research and development (including related party amounts of $667 and $666, respectively) | 4,336 | 2,952 |
| Selling, general and administrative (including related party amounts of $135 and $124, respectively) | 72,204 | 41,104 |
Item 1. Financial Statements
FAQ
- What is ARS Pharmaceuticals, Inc.'s total revenue?
- ARS Pharmaceuticals, Inc. (SPRY) reported total revenue of $22.68M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s total revenue changed year-over-year?
- ARS Pharmaceuticals, Inc.'s total revenue increased by 184.5% year-over-year, from $7.97M to $22.68M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s total revenue?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s total revenue has grown at a 97.8% compound annual growth rate (CAGR), from $5.51M to $84.28M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about ARS Pharmaceuticals, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude